We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

180 hedge funds and large institutions have $835M invested in Allogene Therapeutics in 2022 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 72 increasing their positions, 45 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more call options, than puts

Call options by funds: $1.24M | Put options by funds: $764K

60% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 45

10% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 30

4.06% more ownership

Funds ownership: 60.21% → 64.27% (+4.1%)

2% more funds holding

Funds holding: 177 → 180 (+3)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

35% less capital invested

Capital invested by funds: $1.28B → $835M (-$445M)

Holders
180
Holders Change
+3
Holders Change %
+1.69%
% of All Funds
2.84%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
33
Increased
72
Reduced
45
Closed
30
Calls
$1.24M
Puts
$764K
Net Calls
+$472K
Net Calls Change
+$201K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$36.1M
2
Goldman Sachs
Goldman Sachs
New York
+$11.9M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$10.6M
4
Renaissance Technologies
Renaissance Technologies
New York
+$10.2M
5
Two Sigma Investments
Two Sigma Investments
New York
+$7.96M

Top Sellers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
-$39.5M
2
Capital World Investors
Capital World Investors
California
-$19.4M
3
Marshall Wace
Marshall Wace
United Kingdom
-$14.2M
4
Capital International Investors
Capital International Investors
California
-$10.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
Cerity Partners
26
Cerity Partners
New York
$6.39M -$24.3K -2,333 -0.3%
Northern Trust
27
Northern Trust
Illinois
$6.37M -$267K -25,637 -4%
Capital International Investors
28
Capital International Investors
California
$5.35M -$10.3M -992,031 -63%
Bank of America
29
Bank of America
North Carolina
$5.28M +$3.23M +310,292 +115%
Millennium Management
30
Millennium Management
New York
$5.2M +$4.33M +416,173 +268%
Rafferty Asset Management
31
Rafferty Asset Management
New York
$5.17M +$2.84M +272,539 +92%
Charles Schwab
32
Charles Schwab
California
$4.83M -$66.5K -6,386 -1%
LOAMS
33
Lombard Odier Asset Management (Switzerland)
Switzerland
$4.57M -$5.15M -494,897 -50%
WP
34
Woodline Partners
California
$3.94M -$708K -67,945 -14%
UBS AM
35
UBS AM
Illinois
$3.67M +$134K +12,895 +3%
CBA
36
Coastal Bridge Advisors
Connecticut
$3.66M +$1.04M +100,000 +33%
Deutsche Bank
37
Deutsche Bank
Germany
$3.54M +$461K +44,240 +13%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$2.73M +$5.93K +569 +0.2%
Jacobs Levy Equity Management
39
Jacobs Levy Equity Management
New Jersey
$2.47M +$2.82M +270,737 New
Squarepoint
40
Squarepoint
New York
$2.45M +$2.81M +269,320 New
PP
41
PDT Partners
New York
$2.2M +$578K +55,510 +30%
Principal Financial Group
42
Principal Financial Group
Iowa
$2.16M -$9.46K -908 -0.4%
EVM
43
Eaton Vance Management
Massachusetts
$2.16M – – –
Two Sigma Advisers
44
Two Sigma Advisers
New York
$2.12M +$2.42M +232,500 New
UBS Group
45
UBS Group
Switzerland
$2.03M +$678K +65,126 +41%
Mirae Asset Global Investments
46
Mirae Asset Global Investments
South Korea
$1.95M -$404K -38,829 -15%
CSS
47
Cubist Systematic Strategies
Connecticut
$1.88M +$680K +65,243 +46%
GC
48
Gratus Capital
Georgia
$1.84M +$110K +10,569 +6%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.69M +$140K +13,400 +8%
SG Americas Securities
50
SG Americas Securities
New York
$1.64M +$583K +55,994 +45%
1
2
3 4 5

ALLO Hedge Fund Activity: Q1 2022 in Review

180 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2022, worth a combined $835M — down 35% from $1.28B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ALLO positions and 30 closed out — a net gain of 3 holders — while 72 added to existing stakes and 45 trimmed.

The largest buyer was State Street, adding an estimated $36.1M. The largest seller was Casdin Capital, exiting entirely with an estimated $39.5M sold.

  • 180 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2022, up from 177 in Q4 2021.
  • Funds reported $835M of Allogene Therapeutics stock for Q1 2022, down 35% quarter-over-quarter.
  • 33 funds opened new Allogene Therapeutics positions in Q1 2022 and 30 closed out, a net change of +3 holders.
  • The largest Allogene Therapeutics buyer in Q1 2022 was State Street, an estimated $36.1M added.
  • The largest Allogene Therapeutics seller in Q1 2022 was Casdin Capital, an estimated $39.5M sold.

Based on aggregated 13F filings for Q1 2022.